Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Cell Therapeutics, Inc.

Platinum complexes are cytotoxic agents yet the paradigm in cancer chemotherapy has moved to a more targeted approach, with special emphasis on signaling pathways. In this respect a remarkable story is that of arsenic trioxide, As203 (Trisenox, Cell Therapeutics Inc, Seattle, USA) which was approved by the FDA in September 2000 for treatment of acute promomyelo-cytic leukemia (APL) in patients who have relapsed or are refractory to retinoid and anthracycline chemotherapy. An estimated 1,500 new cases of APL are diagnosed yearly in the US, of which an... [Pg.826]

Dept, of Pharmacology SJ-30, University of Washington, Seattle, WA 98195 and Cell Therapeutics, Inc., Seattle, WA 98195... [Pg.209]

With poly(PGA), a biodegradable polymer backbone is linked to drugs, used primarily as chemotherapy. Conjugates with pa-clitaxel (Cell Therapeutics Inc./Chugai Pharmaceutical Co. Ltd.) showed good results in pre-clinical studies when administered either alone or combined with radiation [37]. A number of clinical studies are also currently under way to determine efficacy against various types of solid tumor [38- 1],... [Pg.1368]

Bristol-Myers Squibb Pharmaceutical Research Institute Campbell and Flores LLP CDR Therapeutics Cell Therapeutics, Inc. [Pg.296]

Cell Therapeutics, Inc., 201 Elliott Avenue West, Suite 400, Seattle, Washington, 98119, USA Corresponding author e mail jsinger ctiseattle.com... [Pg.81]

LisofyUine (84, Scheme 2.13) is a xanthine derivative developed by Cell Therapeutics, Inc. (Seattle, WA) and is used to promote hematopoiesis after chronic blood cell depression following chemotherapy. In the synthesis of liso-fyUine, ( )-pinane diol is employed as a chiral auxiliary in the chlorination of the boronic ester 80. [Pg.54]

Bianco JA, Woodson P, Porubek D, Singer J, inventors Cell Therapeutics, Inc., assignee. R-enantiomerically pure hydroxylated xanthine compounds to treat baldness. US patent 5,567,704. 1996 Oct 22. [Pg.65]

Osiris Therapeutics initiates clinical trial using donor-derived adult stem cells Osiris Therapeutics, Inc. PRESS RELEASE 1999 June 08. [Pg.71]

Cell therapy program Osiris Therapeutics, Inc. COMPANY WORLD WIDE WEB SITE 1999 June 09. [Pg.71]

Osiris licenses stem cell technology to JCR Pharmaceuticals. Osiris Therapeutics, Inc. Press Release, 2003 August 28. [Pg.71]

Changes in IAP expression modulate apoptotic response to cellular stress. For example, an antisense oligonucleotide developed by Aegera Therapeutics, Inc. (Montreal, Quebec, Canada), AEG35156, reduces expression of XIAP. Treatment with AEG3516 increases apoptosis in studies with myeloid leukemia cells, and the antisense approach currently is in phase Eli clinical trials for refractory AML (acute myeloid leukemia) in combination with chemotherapy (29). The strategy of up-regulating IAP action to inhibit apoptosis has been validated... [Pg.1582]

Cornerstone Pharmaceuticals, Cranbury, New Jersey and Stony Brook, New York Altira Capital and Consulting, LLC., Edison, New Jersey Center for Biotechnology, Stony Brook, New York Metabolic Research, Inc., Montgomery, Texas, USA and BrainStorm Cell Therapeutics,... [Pg.157]

Trials of therapeutic vaccination against prostate cancer used OncoVax-P (Jenner Biotherapies, Inc, San Ramon, California). OncoVax-P consists of 200 pg monophosphoryl lipid A (similar to that used in Detox) added to 1 ml liposomes and 100 pg PSA (prostate-specific antigen). Patients received injections by different routes (intramuscular, intravenous or subcutaneous) according to the trial, with or without GM-CSF, IL-2 or BCG and cyclophosphamide pretreatment. No serious side effects were seen. DTH and antibody responses were achieved. Vaccination increased the PSA-reactive T cell frequency as determined by IFN-y secretion, but no toxicity against PSA-expressing target cells was detected. The most effective strategy could not be determined, and no conclusion about the clinical efficacy of the treatment was possible [214,215],... [Pg.545]

StemCells, Inc. is developing a proprietary NSC product for cellular therapy, under license from NeuroSpheres Ltd., comprising well-characterized, normal human CNS stem cells (HuCNS-SCs) from brain tissue. HuCNS-SC is currently under investigation for the potential treatment of neurodegenerative disorders, particularly BD [180367], [540074]. Preclinical studies have been performed in various animal models of CNS diseases and injuries. Data from these studies has supported the therapeutic potential of HuCNS-SCs, and the therapy has recently been approved for a phase I clinical trial for the treatment of BD [629732]. [Pg.44]

See other pages where Cell Therapeutics, Inc. is mentioned: [Pg.476]    [Pg.642]    [Pg.240]    [Pg.307]    [Pg.20]    [Pg.33]    [Pg.35]    [Pg.337]    [Pg.337]    [Pg.20]    [Pg.33]    [Pg.35]    [Pg.77]    [Pg.476]    [Pg.642]    [Pg.240]    [Pg.307]    [Pg.20]    [Pg.33]    [Pg.35]    [Pg.337]    [Pg.337]    [Pg.20]    [Pg.33]    [Pg.35]    [Pg.77]    [Pg.467]    [Pg.475]    [Pg.159]    [Pg.144]    [Pg.413]    [Pg.106]    [Pg.191]    [Pg.52]    [Pg.39]    [Pg.41]    [Pg.51]    [Pg.254]    [Pg.463]    [Pg.1581]   
See also in sourсe #XX -- [ Pg.11 , Pg.74 ]



SEARCH



Cell therapeutics

© 2024 chempedia.info